Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 22;6(4):292-4.
doi: 10.1016/j.chom.2009.09.008.

Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1

Peter D Kwong  1 , John R Mascola, Gary J Nabel
Affiliations

Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1

Peter D Kwong et al. Cell Host Microbe. .

Abstract

Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been isolated. Now, technological advances in sera evaluation, B cell stimulation, microneutralization, and antibody cloning have allowed Burton and colleagues to identify two broadly neutralizing monoclonal antibodies, PG9 and PG16, which provide insights for HIV vaccine design.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Identification of new broadly neutralizing antibodies is dependent on direct screening for neutralization.
Steps involved in the isolation of new broadly neutralizing antibodies are outlined and involve identification of B cell clones with neutralizing antibody activity and direct cloning of immunoglobulins.
Figure 2.
Figure 2.. Neutralization of HIV-1 at a V2-V3 epitope.
Recognition of trimeric HIV-1 Env by PG antibodies (green) requires both a V2-V3 epitope and an associated glycan, whereas the previously defined strain-specific 2909 antibody (blue) requires a V2-V3 epitope and a lysine. (The HIV-1 Env is shown with subunits in red, purple and yellow; gp41 is represented by the small ball at the center of the spike and gp120 as a larger oval with arms labeled V2 and V3.)
See this image and copyright information in PMC

References

    1. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, and Zolla-Pazner S (2005). Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79, 5232–5237. - PMC - PubMed
    1. Mascola JR (2003). Defining the protective antibody response for HIV-1. Curr Mol Med 3, 209–216. - PubMed
    1. Pantophlet R, and Burton DR (2006). GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739–769. - PubMed
    1. Richman DD, Wrin T, Little SJ, and Petropoulos CJ (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144–4149. - PMC - PubMed
    1. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. (2009). Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640. - PubMed

MeSH terms

LinkOut - more resources